ID   DMD_HUMAN               Reviewed;        3685 AA.
AC   P11532; A1L0U9; E7EQR9; E7EQS5; E7ESB2; E9PDN1; E9PDN5; F5GZY3; F8VX32;
AC   Q02295; Q14169; Q14170; Q5JYU0; Q6NSJ9; Q7KZ48; Q8N754; Q9UCW3; Q9UCW4;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 3.
DT   07-OCT-2020, entry version 246.
DE   RecName: Full=Dystrophin;
GN   Name=DMD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS GLY-882; LEU-1469 AND
RP   GLN-2366.
RC   TISSUE=Muscle;
RX   PubMed=3282674; DOI=10.1016/0092-8674(88)90383-2;
RA   Koenig M., Monaco A.P., Kunkel L.M.;
RT   "The complete sequence of dystrophin predicts a rod-shaped cytoskeletal
RT   protein.";
RL   Cell 53:219-228(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS PRO-133; ILE-623;
RP   GLY-784; GLY-882; PHE-1197; ASN-1377; HIS-1745 AND SER-1844.
RX   PubMed=2668885; DOI=10.1093/nar/17.13.5391;
RA   Rosenthal A., Speer A., Billowitz H., Cross G.S., Forrest S.N.,
RA   Davies K.E.;
RT   "Two human cDNA molecules coding for the Duchenne muscular dystrophy (DMD)
RT   locus are highly homologous.";
RL   Nucleic Acids Res. 17:5391-5391(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 15), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=1319059; DOI=10.1073/pnas.89.12.5346;
RA   Lederfein D., Levy Z., Augier N., Mornet D., Morris G., Fuchs O., Yaffe D.,
RA   Nudel U.;
RT   "A 71-kilodalton protein is a major product of the Duchenne muscular
RT   dystrophy gene in brain and other nonmuscle tissues.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:5346-5350(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-2937.
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 6; 13 AND 14).
RC   TISSUE=Brain, Placenta, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-1411 (ISOFORMS 4 AND 5).
RC   TISSUE=Retina;
RA   White R.A.;
RL   Submitted (JAN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-497 (ISOFORM 1).
RX   PubMed=3607877; DOI=10.1016/0092-8674(87)90504-6;
RA   Koenig M., Hoffman E.P., Bertelson C.J., Monaco A.P., Feener C.,
RA   Kunkel L.M.;
RT   "Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and
RT   preliminary genomic organization of the DMD gene in normal and affected
RT   individuals.";
RL   Cell 50:509-517(1987).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-32 (ISOFORM 2), ALTERNATIVE PROMOTER USAGE,
RP   AND ALTERNATIVE SPLICING.
RC   TISSUE=Brain;
RX   PubMed=2648158; DOI=10.1038/338509a0;
RA   Feener C.A., Koenig M., Kunkel L.M.;
RT   "Alternative splicing of human dystrophin mRNA generates isoforms at the
RT   carboxy terminus.";
RL   Nature 338:509-511(1989).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 404-1137, AND VARIANT GLY-882.
RX   PubMed=3428261; DOI=10.1002/j.1460-2075.1987.tb02646.x;
RA   Cross G.S., Speer A., Rosenthal A., Forrest S.M., Smith T.J., Edwards Y.,
RA   Flint T., Hill D., Davies K.E.;
RT   "Deletions of fetal and adult muscle cDNA in Duchenne and Becker muscular
RT   dystrophy patients.";
RL   EMBO J. 6:3277-3283(1987).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 665-722; 2098-2204 AND 2305-2366.
RX   PubMed=3205741; DOI=10.1093/nar/16.23.11141;
RA   Chamberlain J.S., Gibbs R.A., Ranier J.A., Nguyen P.N., Caskey C.T.;
RT   "Deletion screening of the Duchenne muscular dystrophy locus via multiplex
RT   DNA amplification.";
RL   Nucleic Acids Res. 16:11141-11156(1988).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2147-2204.
RX   PubMed=2569720; DOI=10.1093/nar/17.14.5611;
RA   Blonden L.A.J., den Dunnen J.T., van Paassen H.M.B., Wapenaar M.C.,
RA   Grootscholten P.M., Ginjaar H.B., Bakker E., Pearson P.L.,
RA   van Ommen G.J.B.;
RT   "High resolution deletion breakpoint mapping in the DMD gene by whole
RT   cosmid hybridization.";
RL   Nucleic Acids Res. 17:5611-5621(1989).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2305-2364.
RA   Huth A., Will K., Speer A., Bauer D.;
RT   "Differences in introns flanking exon 48 of the DMD/BMD gene.";
RL   Submitted (MAR-1991) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3670-3685, AND TISSUE SPECIFICITY.
RC   TISSUE=Amnion;
RX   PubMed=8541829; DOI=10.1093/hmg/4.9.1475;
RA   Austin R.C., Howard P.L., D'Souza V.N., Klamut H.J., Ray P.N.;
RT   "Cloning and characterization of alternatively spliced isoforms of Dp71.";
RL   Hum. Mol. Genet. 4:1475-1483(1995).
RN   [15]
RP   ANALYSIS OF THE DOMAIN STRUCTURE.
RX   PubMed=2407739;
RA   Koenig M., Kunkel L.M.;
RT   "Detailed analysis of the repeat domain of dystrophin reveals four
RT   potential hinge segments that may confer flexibility.";
RL   J. Biol. Chem. 265:4560-4566(1990).
RN   [16]
RP   INTERACTION WITH DAG1.
RX   PubMed=7592992; DOI=10.1074/jbc.270.45.27305;
RA   Jung D., Yang B., Meyer J., Chamberlain J.S., Campbell K.P.;
RT   "Identification and characterization of the dystrophin anchoring site on
RT   beta-dystroglycan.";
RL   J. Biol. Chem. 270:27305-27310(1995).
RN   [17]
RP   INTERACTION WITH SNTB1.
RX   PubMed=7844150; DOI=10.1083/jcb.128.3.363;
RA   Ahn A.H., Kunkel L.M.;
RT   "Syntrophin binds to an alternatively spliced exon of dystrophin.";
RL   J. Cell Biol. 128:363-371(1995).
RN   [18]
RP   INTERACTION WITH SNTA1 AND SNTB2.
RX   PubMed=8576247; DOI=10.1074/jbc.271.5.2724;
RA   Ahn A.H., Feener C.A., Gussoni E., Yoshida M., Ozawa E., Kunkel L.M.;
RT   "The three human syntrophin genes are expressed in diverse tissues, have
RT   distinct chromosomal locations, and each bind to dystrophin and its
RT   relatives.";
RL   J. Biol. Chem. 271:2724-2730(1996).
RN   [19]
RP   ALTERNATIVE SPLICING (ISOFORMS 15 AND 16), AND DEVELOPMENTAL STAGE.
RC   TISSUE=Telencephalon;
RX   PubMed=9370062; DOI=10.1016/s0165-3806(97)00122-3;
RA   Ceccarini M., Rizzo G., Rosa G., Chelucci C., Macioce P., Petrucci T.C.;
RT   "A splice variant of Dp71 lacking the syntrophin binding site is expressed
RT   in early stages of human neural development.";
RL   Brain Res. Dev. Brain Res. 103:77-82(1997).
RN   [20]
RP   INTERACTION WITH SNTG1 AND SNTG2.
RX   PubMed=10747910; DOI=10.1074/jbc.m000439200;
RA   Piluso G., Mirabella M., Ricci E., Belsito A., Abbondanza C., Servidei S.,
RA   Puca A.A., Tonali P., Puca G.A., Nigro V.;
RT   "Gamma1- and gamma2-syntrophins, two novel dystrophin-binding proteins
RT   localized in neuronal cells.";
RL   J. Biol. Chem. 275:15851-15860(2000).
RN   [21]
RP   ALTERNATIVE SPLICING (ISOFORM 16).
RC   TISSUE=Brain;
RX   PubMed=10734266; DOI=10.1016/s0960-8966(99)00105-4;
RA   Austin R.C., Morris G.E., Howard P.L., Klamut H.J., Ray P.N.;
RT   "Expression and synthesis of alternatively spliced variants of Dp71 in
RT   adult human brain.";
RL   Neuromuscul. Disord. 10:187-193(2000).
RN   [22]
RP   INTERACTION WITH DAG1.
RX   PubMed=11495720; DOI=10.1016/s0898-6568(01)00188-7;
RA   Ilsley J.L., Sudol M., Winder S.J.;
RT   "The interaction of dystrophin with beta-dystroglycan is regulated by
RT   tyrosine phosphorylation.";
RL   Cell. Signal. 13:625-632(2001).
RN   [23]
RP   REVIEW ON ALTERNATIVE PROMOTER USAGE.
RX   PubMed=14636778; DOI=10.1016/s1474-4422(03)00585-4;
RA   Muntoni F., Torelli S., Ferlini A.;
RT   "Dystrophin and mutations: one gene, several proteins, multiple
RT   phenotypes.";
RL   Lancet Neurol. 2:731-740(2003).
RN   [24]
RP   INTERACTION WITH KRT19, AND TISSUE SPECIFICITY.
RX   PubMed=16000376; DOI=10.1091/mbc.e05-02-0112;
RA   Stone M.R., O'Neill A., Catino D., Bloch R.J.;
RT   "Specific interaction of the actin-binding domain of dystrophin with
RT   intermediate filaments containing keratin 19.";
RL   Mol. Biol. Cell 16:4280-4293(2005).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [26]
RP   FUNCTION IN THE DYSTROPHIN-ASSOCIATED GLYCOPROTEIN COMPLEX.
RX   PubMed=16710609; DOI=10.1007/s00018-005-5461-0;
RA   Haenggi T., Fritschy J.M.;
RT   "Role of dystrophin and utrophin for assembly and function of the
RT   dystrophin glycoprotein complex in non-muscle tissue.";
RL   Cell. Mol. Life Sci. 63:1614-1631(2006).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3483; SER-3613; SER-3617;
RP   SER-3623 AND SER-3666, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-340;
RP   SER-344 AND SER-348 (ISOFORMS 13 AND 15), AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3612; SER-3613 AND SER-3623,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3612; SER-3623 AND SER-3624,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3490; SER-3500; SER-3623;
RP   SER-3624 AND SER-3666, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-616
RP   (ISOFORM 15), PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-629 (ISOFORM
RP   14), PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-519 (ISOFORM 16), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 3046-3306 IN COMPLEX WITH DAG1,
RP   AND INTERACTION WITH DAG1.
RX   PubMed=10932245; DOI=10.1038/77923;
RA   Huang X., Poy F., Zhang R., Joachimiak A., Sudol M., Eck M.J.;
RT   "Structure of a WW domain containing fragment of dystrophin in complex with
RT   beta-dystroglycan.";
RL   Nat. Struct. Biol. 7:634-638(2000).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 1-246.
RX   PubMed=10801490; DOI=10.1016/s0969-2126(00)00132-5;
RA   Norwood F.L.M., Sutherland-Smith A.J., Keep N.H., Kendrick-Jones J.;
RT   "The structure of the N-terminal actin-binding domain of human dystrophin
RT   and how mutations in this domain may cause Duchenne or Becker muscular
RT   dystrophy.";
RL   Structure 8:481-491(2000).
RN   [35]
RP   REVIEW ON DMD VARIANTS.
RX   PubMed=7951253; DOI=10.1002/humu.1380040102;
RA   Roberts R.G., Gardner R.J., Bobrow M.;
RT   "Searching for the 1 in 2,400,000: a review of dystrophin gene point
RT   mutations.";
RL   Hum. Mutat. 4:1-11(1994).
RN   [36]
RP   REVIEW ON VARIANTS.
RX   PubMed=8045556; DOI=10.1007/bf00202854;
RA   Rininsland F., Reiss J.;
RT   "Microlesions and polymorphisms in the Duchenne/Becker muscular dystrophy
RT   gene.";
RL   Hum. Genet. 94:111-116(1994).
RN   [37]
RP   VARIANT DMD ARG-54.
RX   PubMed=8401582; DOI=10.1038/ng0893-357;
RA   Prior T.W., Papp A.C., Snyder P.J., Burghes A.H.M., Bartolo C., Sedra M.S.,
RA   Western L.M., Mendell J.R.;
RT   "A missense mutation in the dystrophin gene in a Duchenne muscular
RT   dystrophy patient.";
RL   Nat. Genet. 4:357-360(1993).
RN   [38]
RP   VARIANT DMD GLY-645.
RX   PubMed=7981690; DOI=10.1093/hmg/3.7.1173;
RA   Prior T.W., Bartolo C., Papp A.C., Snyder P.J., Sedra M.S., Burghes A.H.,
RA   Mendell J.R.;
RT   "Identification of a missense mutation, single base deletion and a
RT   polymorphism in the dystrophin exon 16.";
RL   Hum. Mol. Genet. 3:1173-1174(1994).
RN   [39]
RP   VARIANTS HIS-365; TRP-2191 AND ARG-2937.
RX   PubMed=7849724; DOI=10.1093/hmg/3.10.1907;
RA   Nigro V., Nigro G., Esposito M.G., Comi L.I., Molinari A.M., Puca G.A.,
RA   Politano L.;
RT   "Novel small mutations along the DMD/BMD gene associated with different
RT   phenotypes.";
RL   Hum. Mol. Genet. 3:1907-1908(1994).
RN   [40]
RP   VARIANT DMD TYR-3340.
RX   PubMed=8817332; DOI=10.1093/hmg/5.7.973;
RA   Lenk U., Oexle K., Voit T., Ancker U., Hellner K.A., Speer A., Hubner C.;
RT   "A cysteine 3340 substitution in the dystroglycan-binding domain of
RT   dystrophin associated with Duchenne muscular dystrophy, mental retardation
RT   and absence of the ERG b-wave.";
RL   Hum. Mol. Genet. 5:973-975(1996).
RN   [41]
RP   VARIANT CMD3B ALA-279.
RX   PubMed=9170407; DOI=10.1161/01.cir.95.10.2434;
RA   Ortiz-Lopez R., Li H., Su J., Goytia V., Towbin J.A.;
RT   "Evidence for a dystrophin missense mutation as a cause of X-linked dilated
RT   cardiomyopathy.";
RL   Circulation 95:2434-2440(1997).
RN   [42]
RP   VARIANT DMD HIS-3335.
RX   PubMed=9851445; DOI=10.1002/ana.410440619;
RA   Goldberg L.R., Hausmanowa-Petrusewicz I., Fidzianska A., Duggan D.J.,
RA   Steinberg L.S., Hoffman E.P.;
RT   "A dystrophin missense mutation showing persistence of dystrophin and
RT   dystrophin-associated proteins yet a severe phenotype.";
RL   Ann. Neurol. 44:971-976(1998).
RN   [43]
RP   VARIANT BMD PRO-171.
RX   PubMed=10573008; DOI=10.1038/sj.ejhg.5200370;
RA   Eraslan S., Kayserili H., Apak M.Y., Kirdar B.;
RT   "Identification of point mutations in Turkish DMD/BMD families using
RT   multiplex-single stranded conformation analysis (SSCA).";
RL   Eur. J. Hum. Genet. 7:765-770(1999).
RN   [44]
RP   VARIANT LYS-1672.
RX   PubMed=12354438; DOI=10.1016/s0735-1097(02)02126-5;
RA   Feng J., Yan J.Y., Buzin C.H., Sommer S.S., Towbin J.A.;
RT   "Comprehensive mutation scanning of the dystrophin gene in patients with
RT   nonsyndromic X-linked dilated cardiomyopathy.";
RL   J. Am. Coll. Cardiol. 40:1120-1124(2002).
RN   [45]
RP   VARIANTS CMD3B ASN-18 AND LEU-3228, AND VARIANTS TRP-2155; THR-2299;
RP   GLN-2366; VAL-2910; ASP-2912 AND ARG-2937.
RX   PubMed=12359139; DOI=10.1016/s1096-7192(02)00153-1;
RA   Feng J., Yan J., Buzin C.H., Towbin J.A., Sommer S.S.;
RT   "Mutations in the dystrophin gene are associated with sporadic dilated
RT   cardiomyopathy.";
RL   Mol. Genet. Metab. 77:119-126(2002).
RN   [46]
RP   VARIANT DMD PHE-3313, AND VARIANT VAL-165.
RX   PubMed=12632325; DOI=10.1086/374176;
RA   Flanigan K.M., von Niederhausern A., Dunn D.M., Alder J., Mendell J.R.,
RA   Weiss R.B.;
RT   "Rapid direct sequence analysis of the dystrophin gene.";
RL   Am. J. Hum. Genet. 72:931-939(2003).
RN   [47]
RP   VARIANTS [LARGE SCALE ANALYSIS] PHE-334; GLN-1219; HIS-1470 AND VAL-2164.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [48]
RP   VARIANT ARG-118.
RX   PubMed=21396098; DOI=10.1186/1471-2350-12-37;
RA   Magri F., Del Bo R., D'Angelo M.G., Govoni A., Ghezzi S., Gandossini S.,
RA   Sciacco M., Ciscato P., Bordoni A., Tedeschi S., Fortunato F., Lucchini V.,
RA   Cereda M., Corti S., Moggio M., Bresolin N., Comi G.P.;
RT   "Clinical and molecular characterization of a cohort of patients with novel
RT   nucleotide alterations of the Dystrophin gene detected by direct
RT   sequencing.";
RL   BMC Med. Genet. 12:37-37(2011).
RN   [49]
RP   CHARACTERIZATION OF VARIANTS DMD PHE-3313; HIS-3335 AND TYR-3340.
RX   PubMed=24302611; DOI=10.1002/humu.22479;
RA   Vulin A., Wein N., Strandjord D.M., Johnson E.K., Findlay A.R., Maiti B.,
RA   Howard M.T., Kaminoh Y.J., Taylor L.E., Simmons T.R., Ray W.C.,
RA   Montanaro F., Ervasti J.M., Flanigan K.M.;
RT   "The ZZ domain of dystrophin in DMD: making sense of missense mutations.";
RL   Hum. Mutat. 35:257-264(2014).
RN   [50]
RP   CHARACTERIZATION OF VARIANT CMD3B ASN-18.
RX   PubMed=25340340; DOI=10.1371/journal.pone.0110439;
RA   Singh S.M., Bandi S., Shah D.D., Armstrong G., Mallela K.M.;
RT   "Missense mutation Lys18Asn in dystrophin that triggers X-linked dilated
RT   cardiomyopathy decreases protein stability, increases protein unfolding,
RT   and perturbs protein structure, but does not affect protein function.";
RL   PLoS ONE 9:E110439-E110439(2014).
CC   -!- FUNCTION: Anchors the extracellular matrix to the cytoskeleton via F-
CC       actin. Ligand for dystroglycan. Component of the dystrophin-associated
CC       glycoprotein complex which accumulates at the neuromuscular junction
CC       (NMJ) and at a variety of synapses in the peripheral and central
CC       nervous systems and has a structural function in stabilizing the
CC       sarcolemma. Also implicated in signaling events and synaptic
CC       transmission. {ECO:0000250|UniProtKB:P11531,
CC       ECO:0000269|PubMed:16710609}.
CC   -!- SUBUNIT: Interacts with SYNM (By similarity). Interacts with the
CC       syntrophins SNTA1, SNTB1, SNTB2, SNTG1 and SNTG2 (PubMed:7844150,
CC       PubMed:8576247). Interacts with KRT19 (PubMed:16000376). Component of
CC       the dystrophin-associated glycoprotein complex which is composed of
CC       three subcomplexes: a cytoplasmic complex comprised of DMD (or UTRN),
CC       DTNA and a number of syntrophins, such as SNTB1, SNTB2, SNTG1 and
CC       SNTG2, the transmembrane dystroglycan complex, and the sarcoglycan-
CC       sarcospan complex. Interacts with DAG1 (betaDAG1) with DMD; the
CC       interaction is inhibited by phosphorylation on the PPXY motif of DAG1
CC       (PubMed:7592992, PubMed:11495720, PubMed:10932245). Interacts with
CC       CMYA5 (By similarity). Directly interacts with ANK2 and ANK3; these
CC       interactions do not interfere with betaDAG1-binding and are necessary
CC       for proper localization in muscle cells (By similarity). Identified in
CC       a dystroglycan complex that contains at least PRX, DRP2, UTRN, DMD and
CC       DAG1 (By similarity). {ECO:0000250|UniProtKB:P11531,
CC       ECO:0000269|PubMed:10932245, ECO:0000269|PubMed:11495720,
CC       ECO:0000269|PubMed:16000376, ECO:0000269|PubMed:7592992,
CC       ECO:0000269|PubMed:7844150, ECO:0000269|PubMed:8576247}.
CC   -!- INTERACTION:
CC       P11532; Q9UBT7: CTNNAL1; NbExp=8; IntAct=EBI-295827, EBI-514206;
CC       P11532; Q9NRI5: DISC1; NbExp=3; IntAct=EBI-295827, EBI-529989;
CC       P11532; O60941: DTNB; NbExp=4; IntAct=EBI-295827, EBI-740402;
CC       P11532; O60941-5: DTNB; NbExp=3; IntAct=EBI-295827, EBI-11984733;
CC       P11532; Q96CS2: HAUS1; NbExp=4; IntAct=EBI-295827, EBI-2514791;
CC       P11532; P41235-3: HNF4A; NbExp=3; IntAct=EBI-295827, EBI-12690684;
CC       P11532; P08727: KRT19; NbExp=2; IntAct=EBI-295827, EBI-742756;
CC       P11532; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-295827, EBI-79165;
CC       P11532; Q13884: SNTB1; NbExp=4; IntAct=EBI-295827, EBI-295843;
CC       P11532; Q13425: SNTB2; NbExp=2; IntAct=EBI-295827, EBI-80411;
CC       P11532-5; Q01484: ANK2; NbExp=2; IntAct=EBI-1018651, EBI-941975;
CC       P11532-5; Q3T1J5: Ank3; Xeno; NbExp=2; IntAct=EBI-1018651, EBI-2133962;
CC   -!- SUBCELLULAR LOCATION: Cell membrane, sarcolemma
CC       {ECO:0000250|UniProtKB:P11531}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:P11531}; Cytoplasmic side
CC       {ECO:0000250|UniProtKB:P11531}. Cytoplasm, cytoskeleton
CC       {ECO:0000250|UniProtKB:P11531}. Cell junction, synapse, postsynaptic
CC       cell membrane {ECO:0000250|UniProtKB:P11531}. Note=In muscle cells,
CC       sarcolemma localization requires the presence of ANK2, while
CC       localization to costameres requires the presence of ANK3. Localizes to
CC       neuromuscular junctions (NMJs). In adult muscle, NMJ localization
CC       depends upon ANK2 presence, but not in newborn animals.
CC       {ECO:0000250|UniProtKB:P11531}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=17;
CC       Name=1; Synonyms=Dystrophin-4, Dp427m;
CC         IsoId=P11532-1; Sequence=Displayed;
CC       Name=2; Synonyms=Dystrophin-3, Dp427c;
CC         IsoId=P11532-4; Sequence=VSP_006809;
CC       Name=3; Synonyms=Dp427p;
CC         IsoId=P11532-11; Sequence=VSP_060274;
CC       Name=4; Synonyms=Dystrophin-1, Dp260-1;
CC         IsoId=P11532-2; Sequence=VSP_006806, VSP_006807;
CC       Name=5; Synonyms=Dystrophin-2, Dp260-2;
CC         IsoId=P11532-3; Sequence=VSP_006808, VSP_006807;
CC       Name=6; Synonyms=Dp140;
CC         IsoId=P11532-12; Sequence=VSP_060275;
CC       Name=7; Synonyms=Dp140c;
CC         IsoId=P11532-13; Sequence=VSP_060275, VSP_046319;
CC       Name=8; Synonyms=Dp140b;
CC         IsoId=P11532-14; Sequence=VSP_060275, VSP_017493;
CC       Name=9; Synonyms=Dp140ab;
CC         IsoId=P11532-15; Sequence=VSP_060275, VSP_017492, VSP_017493;
CC       Name=10; Synonyms=Dp140bc;
CC         IsoId=P11532-16; Sequence=VSP_060275, VSP_046319, VSP_017493;
CC       Name=11; Synonyms=Dp116;
CC         IsoId=P11532-17; Sequence=VSP_060276, VSP_060277;
CC       Name=12; Synonyms=Dp71;
CC         IsoId=P11532-7; Sequence=VSP_017490, VSP_017491;
CC       Name=13; Synonyms=Dp71a;
CC         IsoId=P11532-8; Sequence=VSP_017490, VSP_017491, VSP_017492;
CC       Name=14; Synonyms=Dp71b;
CC         IsoId=P11532-6; Sequence=VSP_017490, VSP_017491, VSP_017493;
CC       Name=15; Synonyms=Dp71ab;
CC         IsoId=P11532-5; Sequence=VSP_017490, VSP_017491, VSP_017492,
CC                                  VSP_017493;
CC       Name=16; Synonyms=Dp60, Dp71delta110;
CC         IsoId=P11532-9; Sequence=VSP_017490, VSP_017491, VSP_046319,
CC                                  VSP_017493;
CC       Name=17; Synonyms=Dp40;
CC         IsoId=P11532-18; Sequence=VSP_017490, VSP_017491, VSP_060278;
CC   -!- TISSUE SPECIFICITY: Expressed in muscle fibers accumulating in the
CC       costameres of myoplasm at the sarcolemma. Expressed in brain, muscle,
CC       kidney, lung and testis. Most tissues contain transcripts of multiple
CC       isoforms. Isoform 15: Only isoform to be detected in heart and liver
CC       and is also expressed in brain, testis and hepatoma cells.
CC       {ECO:0000269|PubMed:1319059, ECO:0000269|PubMed:16000376,
CC       ECO:0000269|PubMed:8541829}.
CC   -!- DEVELOPMENTAL STAGE: Isoform 15: Expressed in embryonic neural tissue
CC       from the sixth week of development. Isoform 16: Detected in all
CC       embryonic tissues examined. {ECO:0000269|PubMed:9370062}.
CC   -!- DISEASE: Duchenne muscular dystrophy (DMD) [MIM:310200]: Most common
CC       form of muscular dystrophy; a sex-linked recessive disorder. It
CC       typically presents in boys aged 3 to 7 year as proximal muscle weakness
CC       causing waddling gait, toe-walking, lordosis, frequent falls, and
CC       difficulty in standing up and climbing up stairs. The pelvic girdle is
CC       affected first, then the shoulder girdle. Progression is steady and
CC       most patients are confined to a wheelchair by age of 10 or 12. Flexion
CC       contractures and scoliosis ultimately occur. About 50% of patients have
CC       a lower IQ than their genetic expectations would suggest. There is no
CC       treatment. {ECO:0000269|PubMed:12632325, ECO:0000269|PubMed:24302611,
CC       ECO:0000269|PubMed:7981690, ECO:0000269|PubMed:8401582,
CC       ECO:0000269|PubMed:8817332, ECO:0000269|PubMed:9851445}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Becker muscular dystrophy (BMD) [MIM:300376]: A neuromuscular
CC       disorder characterized by dystrophin deficiency. It appears between the
CC       age of 5 and 15 years with a proximal motor deficiency of variable
CC       progression. Heart involvement can be the initial sign. Becker muscular
CC       dystrophy has a more benign course than Duchenne muscular dystrophy.
CC       {ECO:0000269|PubMed:10573008}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Cardiomyopathy, dilated, X-linked 3B (CMD3B) [MIM:302045]: A
CC       disorder characterized by ventricular dilation and impaired systolic
CC       function, resulting in congestive heart failure and arrhythmia.
CC       Patients are at risk of premature death. {ECO:0000269|PubMed:12359139,
CC       ECO:0000269|PubMed:25340340, ECO:0000269|PubMed:9170407}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: The DMD gene is the largest known gene in humans. It is
CC       2.4 million base-pairs in size, comprises 79 exons and takes over 16
CC       hours to be transcribed and cotranscriptionally spliced.
CC   -!- MISCELLANEOUS: [Isoform 1]: Produced by alternative promoter usage.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Produced by alternative splicing of isoform
CC       4. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 6]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative splicing of isoform
CC       6. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative splicing of isoform
CC       6. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 9]: Produced by alternative splicing of isoform
CC       6. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 10]: Produced by alternative splicing of
CC       isoform 6. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 11]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 12]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 13]: Produced by alternative splicing of
CC       isoform 12. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 14]: Produced by alternative splicing of
CC       isoform 12. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 15]: Produced by alternative splicing of
CC       isoform 12. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 16]: Produced by alternative splicing of
CC       isoform 12. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 17]: Produced by alternative splicing of
CC       isoform 12. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=DMD; Note=Dystrophin Mutation Database;
CC       URL="http://www.dmd.nl/database.html";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=DMD";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Dystrophin entry;
CC       URL="https://en.wikipedia.org/wiki/Dystrophin";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M18533; AAA53189.1; -; mRNA.
DR   EMBL; X14298; CAA32479.1; -; mRNA.
DR   EMBL; M92650; AAA52316.1; -; mRNA.
DR   EMBL; AC078957; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL031542; CAI42229.1; -; Genomic_DNA.
DR   EMBL; AC004468; CAI42229.1; JOINED; Genomic_DNA.
DR   EMBL; AC006061; CAI42229.1; JOINED; Genomic_DNA.
DR   EMBL; AC078958; CAI42229.1; JOINED; Genomic_DNA.
DR   EMBL; AC079143; CAI42229.1; JOINED; Genomic_DNA.
DR   EMBL; AC079175; CAI42229.1; JOINED; Genomic_DNA.
DR   EMBL; AC079177; CAI42229.1; JOINED; Genomic_DNA.
DR   EMBL; AC079864; CAI42229.1; JOINED; Genomic_DNA.
DR   EMBL; AC090632; CAI42229.1; JOINED; Genomic_DNA.
DR   EMBL; AC093167; CAI42229.1; JOINED; Genomic_DNA.
DR   EMBL; AC093193; CAI42229.1; JOINED; Genomic_DNA.
DR   EMBL; AC096506; CAI42229.1; JOINED; Genomic_DNA.
DR   EMBL; AL031643; CAI42229.1; JOINED; Genomic_DNA.
DR   EMBL; AL096699; CAI42229.1; JOINED; Genomic_DNA.
DR   EMBL; AL109609; CAI42229.1; JOINED; Genomic_DNA.
DR   EMBL; AL139278; CAI42229.1; JOINED; Genomic_DNA.
DR   EMBL; AL451144; CAI42229.1; JOINED; Genomic_DNA.
DR   EMBL; AL031643; CAI43058.1; -; Genomic_DNA.
DR   EMBL; AC004468; CAI43058.1; JOINED; Genomic_DNA.
DR   EMBL; AC006061; CAI43058.1; JOINED; Genomic_DNA.
DR   EMBL; AC078958; CAI43058.1; JOINED; Genomic_DNA.
DR   EMBL; AC079143; CAI43058.1; JOINED; Genomic_DNA.
DR   EMBL; AC079175; CAI43058.1; JOINED; Genomic_DNA.
DR   EMBL; AC079177; CAI43058.1; JOINED; Genomic_DNA.
DR   EMBL; AC079864; CAI43058.1; JOINED; Genomic_DNA.
DR   EMBL; AC090632; CAI43058.1; JOINED; Genomic_DNA.
DR   EMBL; AC093167; CAI43058.1; JOINED; Genomic_DNA.
DR   EMBL; AC093193; CAI43058.1; JOINED; Genomic_DNA.
DR   EMBL; AC096506; CAI43058.1; JOINED; Genomic_DNA.
DR   EMBL; AL031542; CAI43058.1; JOINED; Genomic_DNA.
DR   EMBL; AL096699; CAI43058.1; JOINED; Genomic_DNA.
DR   EMBL; AL109609; CAI43058.1; JOINED; Genomic_DNA.
DR   EMBL; AL139278; CAI43058.1; JOINED; Genomic_DNA.
DR   EMBL; AL451144; CAI43058.1; JOINED; Genomic_DNA.
DR   EMBL; AL049643; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL050305; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL096699; CAI42225.1; -; Genomic_DNA.
DR   EMBL; AC004468; CAI42225.1; JOINED; Genomic_DNA.
DR   EMBL; AC006061; CAI42225.1; JOINED; Genomic_DNA.
DR   EMBL; AC078958; CAI42225.1; JOINED; Genomic_DNA.
DR   EMBL; AC079143; CAI42225.1; JOINED; Genomic_DNA.
DR   EMBL; AC079175; CAI42225.1; JOINED; Genomic_DNA.
DR   EMBL; AC079177; CAI42225.1; JOINED; Genomic_DNA.
DR   EMBL; AC079864; CAI42225.1; JOINED; Genomic_DNA.
DR   EMBL; AC090632; CAI42225.1; JOINED; Genomic_DNA.
DR   EMBL; AC093167; CAI42225.1; JOINED; Genomic_DNA.
DR   EMBL; AC093193; CAI42225.1; JOINED; Genomic_DNA.
DR   EMBL; AC096506; CAI42225.1; JOINED; Genomic_DNA.
DR   EMBL; AL031542; CAI42225.1; JOINED; Genomic_DNA.
DR   EMBL; AL031643; CAI42225.1; JOINED; Genomic_DNA.
DR   EMBL; AL109609; CAI42225.1; JOINED; Genomic_DNA.
DR   EMBL; AL139278; CAI42225.1; JOINED; Genomic_DNA.
DR   EMBL; AL451144; CAI42225.1; JOINED; Genomic_DNA.
DR   EMBL; AL109609; CAI42950.1; -; Genomic_DNA.
DR   EMBL; AC004468; CAI42950.1; JOINED; Genomic_DNA.
DR   EMBL; AC006061; CAI42950.1; JOINED; Genomic_DNA.
DR   EMBL; AC078958; CAI42950.1; JOINED; Genomic_DNA.
DR   EMBL; AC079143; CAI42950.1; JOINED; Genomic_DNA.
DR   EMBL; AC079175; CAI42950.1; JOINED; Genomic_DNA.
DR   EMBL; AC079177; CAI42950.1; JOINED; Genomic_DNA.
DR   EMBL; AC079864; CAI42950.1; JOINED; Genomic_DNA.
DR   EMBL; AC090632; CAI42950.1; JOINED; Genomic_DNA.
DR   EMBL; AC093167; CAI42950.1; JOINED; Genomic_DNA.
DR   EMBL; AC093193; CAI42950.1; JOINED; Genomic_DNA.
DR   EMBL; AC096506; CAI42950.1; JOINED; Genomic_DNA.
DR   EMBL; AL031542; CAI42950.1; JOINED; Genomic_DNA.
DR   EMBL; AL031643; CAI42950.1; JOINED; Genomic_DNA.
DR   EMBL; AL096699; CAI42950.1; JOINED; Genomic_DNA.
DR   EMBL; AL139278; CAI42950.1; JOINED; Genomic_DNA.
DR   EMBL; AL451144; CAI42950.1; JOINED; Genomic_DNA.
DR   EMBL; AL121880; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL139278; CAI42991.1; -; Genomic_DNA.
DR   EMBL; AC004468; CAI42991.1; JOINED; Genomic_DNA.
DR   EMBL; AC006061; CAI42991.1; JOINED; Genomic_DNA.
DR   EMBL; AC078958; CAI42991.1; JOINED; Genomic_DNA.
DR   EMBL; AC079143; CAI42991.1; JOINED; Genomic_DNA.
DR   EMBL; AC079175; CAI42991.1; JOINED; Genomic_DNA.
DR   EMBL; AC079177; CAI42991.1; JOINED; Genomic_DNA.
DR   EMBL; AC079864; CAI42991.1; JOINED; Genomic_DNA.
DR   EMBL; AC090632; CAI42991.1; JOINED; Genomic_DNA.
DR   EMBL; AC093167; CAI42991.1; JOINED; Genomic_DNA.
DR   EMBL; AC093193; CAI42991.1; JOINED; Genomic_DNA.
DR   EMBL; AC096506; CAI42991.1; JOINED; Genomic_DNA.
DR   EMBL; AL031542; CAI42991.1; JOINED; Genomic_DNA.
DR   EMBL; AL031643; CAI42991.1; JOINED; Genomic_DNA.
DR   EMBL; AL096699; CAI42991.1; JOINED; Genomic_DNA.
DR   EMBL; AL109609; CAI42991.1; JOINED; Genomic_DNA.
DR   EMBL; AL451144; CAI42991.1; JOINED; Genomic_DNA.
DR   EMBL; AL139401; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL451144; CAI39566.1; -; Genomic_DNA.
DR   EMBL; AC004468; CAI39566.1; JOINED; Genomic_DNA.
DR   EMBL; AC006061; CAI39566.1; JOINED; Genomic_DNA.
DR   EMBL; AC078958; CAI39566.1; JOINED; Genomic_DNA.
DR   EMBL; AC079143; CAI39566.1; JOINED; Genomic_DNA.
DR   EMBL; AC079175; CAI39566.1; JOINED; Genomic_DNA.
DR   EMBL; AC079177; CAI39566.1; JOINED; Genomic_DNA.
DR   EMBL; AC079864; CAI39566.1; JOINED; Genomic_DNA.
DR   EMBL; AC090632; CAI39566.1; JOINED; Genomic_DNA.
DR   EMBL; AC093167; CAI39566.1; JOINED; Genomic_DNA.
DR   EMBL; AC093193; CAI39566.1; JOINED; Genomic_DNA.
DR   EMBL; AC096506; CAI39566.1; JOINED; Genomic_DNA.
DR   EMBL; AL031542; CAI39566.1; JOINED; Genomic_DNA.
DR   EMBL; AL031643; CAI39566.1; JOINED; Genomic_DNA.
DR   EMBL; AL096699; CAI39566.1; JOINED; Genomic_DNA.
DR   EMBL; AL109609; CAI39566.1; JOINED; Genomic_DNA.
DR   EMBL; AL139278; CAI39566.1; JOINED; Genomic_DNA.
DR   EMBL; AL596023; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471074; EAW99065.1; -; Genomic_DNA.
DR   EMBL; BC028720; AAH28720.1; -; mRNA.
DR   EMBL; BC070078; AAH70078.1; -; mRNA.
DR   EMBL; BC094758; AAH94758.1; -; mRNA.
DR   EMBL; BC127103; AAI27104.2; -; mRNA.
DR   EMBL; U27203; AAA86115.1; -; Genomic_DNA.
DR   EMBL; U27203; AAA86116.1; -; Genomic_DNA.
DR   EMBL; X15148; CAA33245.1; -; mRNA.
DR   EMBL; X06178; CAA29544.1; -; mRNA.
DR   EMBL; X06179; CAA29545.1; -; mRNA.
DR   EMBL; X13045; CAA31451.1; -; Genomic_DNA.
DR   EMBL; X13046; CAA31452.1; -; Genomic_DNA.
DR   EMBL; X13047; CAA31453.1; -; Genomic_DNA.
DR   EMBL; X13048; CAA31454.1; -; Genomic_DNA.
DR   EMBL; X15495; CAA33518.1; -; Genomic_DNA.
DR   EMBL; X54820; CAA38589.1; -; Genomic_DNA.
DR   CCDS; CCDS14231.1; -. [P11532-6]
DR   CCDS; CCDS14232.1; -. [P11532-5]
DR   CCDS; CCDS14233.1; -. [P11532-1]
DR   CCDS; CCDS14234.1; -. [P11532-7]
DR   CCDS; CCDS48091.1; -. [P11532-12]
DR   CCDS; CCDS55394.1; -. [P11532-13]
DR   CCDS; CCDS55395.1; -. [P11532-11]
DR   CCDS; CCDS75965.1; -. [P11532-17]
DR   PIR; A45255; A45255.
DR   RefSeq; NP_000100.2; NM_000109.3.
DR   RefSeq; NP_003997.1; NM_004006.2.
DR   RefSeq; NP_004000.1; NM_004009.3.
DR   RefSeq; NP_004001.1; NM_004010.3.
DR   RefSeq; NP_004002.2; NM_004011.3.
DR   RefSeq; NP_004003.1; NM_004012.3.
DR   RefSeq; NP_004004.1; NM_004013.2. [P11532-12]
DR   RefSeq; NP_004005.1; NM_004014.2. [P11532-17]
DR   RefSeq; NP_004006.1; NM_004015.2. [P11532-7]
DR   RefSeq; NP_004007.1; NM_004016.2. [P11532-6]
DR   RefSeq; NP_004008.1; NM_004017.2. [P11532-8]
DR   RefSeq; NP_004009.1; NM_004018.2. [P11532-5]
DR   RefSeq; NP_004010.1; NM_004019.2. [P11532-18]
DR   RefSeq; NP_004011.2; NM_004020.3. [P11532-13]
DR   RefSeq; NP_004012.1; NM_004021.2.
DR   RefSeq; NP_004013.1; NM_004022.2. [P11532-15]
DR   RefSeq; NP_004014.1; NM_004023.2.
DR   PDB; 1DXX; X-ray; 2.60 A; A/B/C/D=1-246.
DR   PDB; 1EG3; X-ray; 2.00 A; A=3046-3306.
DR   PDB; 1EG4; X-ray; 2.00 A; A=3046-3306.
DR   PDB; 3UUN; X-ray; 2.30 A; A/B=338-456.
DR   PDBsum; 1DXX; -.
DR   PDBsum; 1EG3; -.
DR   PDBsum; 1EG4; -.
DR   PDBsum; 3UUN; -.
DR   SASBDB; P11532; -.
DR   SMR; P11532; -.
DR   BioGRID; 108096; 65.
DR   DIP; DIP-32593N; -.
DR   IntAct; P11532; 54.
DR   MINT; P11532; -.
DR   STRING; 9606.ENSP00000354923; -.
DR   DrugBank; DB15593; Golodirsen.
DR   TCDB; 8.A.66.1.2; the dystrophin (dystrophin) family.
DR   CarbonylDB; P11532; -.
DR   iPTMnet; P11532; -.
DR   PhosphoSitePlus; P11532; -.
DR   SwissPalm; P11532; -.
DR   BioMuta; DMD; -.
DR   DMDM; 313104240; -.
DR   EPD; P11532; -.
DR   jPOST; P11532; -.
DR   MassIVE; P11532; -.
DR   MaxQB; P11532; -.
DR   PaxDb; P11532; -.
DR   PeptideAtlas; P11532; -.
DR   PRIDE; P11532; -.
DR   ProteomicsDB; 17631; -.
DR   ProteomicsDB; 17635; -.
DR   ProteomicsDB; 17951; -.
DR   ProteomicsDB; 19709; -.
DR   ProteomicsDB; 19712; -.
DR   ProteomicsDB; 25166; -.
DR   ProteomicsDB; 29059; -.
DR   ProteomicsDB; 52788; -. [P11532-1]
DR   ProteomicsDB; 52789; -. [P11532-2]
DR   ProteomicsDB; 52790; -. [P11532-3]
DR   ProteomicsDB; 52791; -. [P11532-4]
DR   ProteomicsDB; 52792; -. [P11532-5]
DR   ProteomicsDB; 52793; -. [P11532-6]
DR   Antibodypedia; 476; 613 antibodies.
DR   DNASU; 1756; -.
DR   Ensembl; ENST00000361471; ENSP00000354464; ENSG00000198947. [P11532-5]
DR   Ensembl; ENST00000378680; ENSP00000367951; ENSG00000198947. [P11532-9]
DR   Ensembl; ENST00000378702; ENSP00000367974; ENSG00000198947. [P11532-7]
DR   Ensembl; ENST00000378723; ENSP00000367997; ENSG00000198947. [P11532-6]
DR   GeneID; 1756; -.
DR   KEGG; hsa:1756; -.
DR   UCSC; uc004dcm.2; human. [P11532-1]
DR   UCSC; uc004dcq.1; human.
DR   UCSC; uc004dcr.1; human.
DR   UCSC; uc004dct.1; human.
DR   UCSC; uc004dcu.2; human.
DR   UCSC; uc004dcv.1; human.
DR   UCSC; uc004dcy.2; human.
DR   CTD; 1756; -.
DR   DisGeNET; 1756; -.
DR   EuPathDB; HostDB:ENSG00000198947.15; -.
DR   GeneCards; DMD; -.
DR   GeneReviews; DMD; -.
DR   HGNC; HGNC:2928; DMD.
DR   HPA; ENSG00000198947; Low tissue specificity.
DR   MalaCards; DMD; -.
DR   MIM; 300376; phenotype.
DR   MIM; 300377; gene.
DR   MIM; 302045; phenotype.
DR   MIM; 310200; phenotype.
DR   neXtProt; NX_P11532; -.
DR   OpenTargets; ENSG00000198947; -.
DR   Orphanet; 98895; Becker muscular dystrophy.
DR   Orphanet; 98896; Duchenne muscular dystrophy.
DR   Orphanet; 154; Familial isolated dilated cardiomyopathy.
DR   Orphanet; 206546; Symptomatic form of muscular dystrophy of Duchenne and Becker in female carriers.
DR   Orphanet; 777; X-linked non-syndromic intellectual disability.
DR   PharmGKB; PA27378; -.
DR   eggNOG; KOG4286; Eukaryota.
DR   GeneTree; ENSGT00940000154342; -.
DR   HOGENOM; CLU_001187_1_2_1; -.
DR   InParanoid; P11532; -.
DR   KO; K10366; -.
DR   OrthoDB; 924518at2759; -.
DR   PhylomeDB; P11532; -.
DR   TreeFam; TF320178; -.
DR   PathwayCommons; P11532; -.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-HSA-390522; Striated Muscle Contraction.
DR   SignaLink; P11532; -.
DR   SIGNOR; P11532; -.
DR   BioGRID-ORCS; 1756; 2 hits in 505 CRISPR screens.
DR   ChiTaRS; DMD; human.
DR   EvolutionaryTrace; P11532; -.
DR   GeneWiki; Dystrophin; -.
DR   GenomeRNAi; 1756; -.
DR   Pharos; P11532; Tbio.
DR   PRO; PR:P11532; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P11532; protein.
DR   Bgee; ENSG00000198947; Expressed in trigeminal ganglion and 247 other tissues.
DR   ExpressionAtlas; P11532; baseline and differential.
DR   Genevisible; P11532; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0030055; C:cell-substrate junction; ISS:BHF-UCL.
DR   GO; GO:0043034; C:costamere; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016010; C:dystrophin-associated glycoprotein complex; IDA:UniProtKB.
DR   GO; GO:0030175; C:filopodium; IDA:BHF-UCL.
DR   GO; GO:0031527; C:filopodium membrane; IDA:BHF-UCL.
DR   GO; GO:0045121; C:membrane raft; ISS:BHF-UCL.
DR   GO; GO:0044306; C:neuron projection terminus; ISS:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:BHF-UCL.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0032991; C:protein-containing complex; IDA:MGI.
DR   GO; GO:0042383; C:sarcolemma; IDA:BHF-UCL.
DR   GO; GO:0045202; C:synapse; ISS:BHF-UCL.
DR   GO; GO:0016013; C:syntrophin complex; TAS:BHF-UCL.
DR   GO; GO:0030018; C:Z disc; ISS:BHF-UCL.
DR   GO; GO:0003779; F:actin binding; IDA:BHF-UCL.
DR   GO; GO:0002162; F:dystroglycan binding; IPI:UniProtKB.
DR   GO; GO:0017022; F:myosin binding; IDA:BHF-UCL.
DR   GO; GO:0050998; F:nitric-oxide synthase binding; ISS:BHF-UCL.
DR   GO; GO:0005200; F:structural constituent of cytoskeleton; TAS:ProtInc.
DR   GO; GO:0008307; F:structural constituent of muscle; IDA:UniProtKB.
DR   GO; GO:0017166; F:vinculin binding; IPI:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0086001; P:cardiac muscle cell action potential; ISS:BHF-UCL.
DR   GO; GO:0060048; P:cardiac muscle contraction; IMP:BHF-UCL.
DR   GO; GO:0034613; P:cellular protein localization; IMP:BHF-UCL.
DR   GO; GO:0034622; P:cellular protein-containing complex assembly; ISS:BHF-UCL.
DR   GO; GO:0035633; P:maintenance of blood-brain barrier; NAS:ARUK-UCL.
DR   GO; GO:0044458; P:motile cilium assembly; TAS:BHF-UCL.
DR   GO; GO:0046716; P:muscle cell cellular homeostasis; ISS:BHF-UCL.
DR   GO; GO:0048747; P:muscle fiber development; ISS:BHF-UCL.
DR   GO; GO:0030049; P:muscle filament sliding; TAS:Reactome.
DR   GO; GO:0007517; P:muscle organ development; NAS:ProtInc.
DR   GO; GO:1902083; P:negative regulation of peptidyl-cysteine S-nitrosylation; ISS:BHF-UCL.
DR   GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0043043; P:peptide biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IMP:BHF-UCL.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:2000651; P:positive regulation of sodium ion transmembrane transporter activity; ISS:BHF-UCL.
DR   GO; GO:0010881; P:regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion; ISS:BHF-UCL.
DR   GO; GO:0090287; P:regulation of cellular response to growth factor stimulus; IMP:BHF-UCL.
DR   GO; GO:0002027; P:regulation of heart rate; IMP:BHF-UCL.
DR   GO; GO:0010880; P:regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum; ISS:BHF-UCL.
DR   GO; GO:0060314; P:regulation of ryanodine-sensitive calcium-release channel activity; ISS:BHF-UCL.
DR   GO; GO:0014819; P:regulation of skeletal muscle contraction; ISS:BHF-UCL.
DR   GO; GO:0014809; P:regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion; ISS:BHF-UCL.
DR   GO; GO:1901385; P:regulation of voltage-gated calcium channel activity; ISS:BHF-UCL.
DR   GO; GO:0035994; P:response to muscle stretch; ISS:BHF-UCL.
DR   CDD; cd00014; CH; 2.
DR   CDD; cd00201; WW; 1.
DR   Gene3D; 1.10.418.10; -; 2.
DR   Gene3D; 3.30.60.90; -; 1.
DR   IDEAL; IID00267; -.
DR   InterPro; IPR001589; Actinin_actin-bd_CS.
DR   InterPro; IPR001715; CH-domain.
DR   InterPro; IPR036872; CH_dom_sf.
DR   InterPro; IPR035436; Dystrophin/utrophin.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR015153; EF-hand_dom_typ1.
DR   InterPro; IPR015154; EF-hand_dom_typ2.
DR   InterPro; IPR018159; Spectrin/alpha-actinin.
DR   InterPro; IPR002017; Spectrin_repeat.
DR   InterPro; IPR001202; WW_dom.
DR   InterPro; IPR036020; WW_dom_sf.
DR   InterPro; IPR000433; Znf_ZZ.
DR   InterPro; IPR043145; Znf_ZZ_sf.
DR   Pfam; PF00307; CH; 2.
DR   Pfam; PF09068; EF-hand_2; 1.
DR   Pfam; PF09069; EF-hand_3; 1.
DR   Pfam; PF00435; Spectrin; 17.
DR   Pfam; PF00397; WW; 1.
DR   Pfam; PF00569; ZZ; 1.
DR   PIRSF; PIRSF002341; Dystrophin/utrophin; 1.
DR   SMART; SM00033; CH; 2.
DR   SMART; SM00150; SPEC; 22.
DR   SMART; SM00456; WW; 1.
DR   SMART; SM00291; ZnF_ZZ; 1.
DR   SUPFAM; SSF47473; SSF47473; 2.
DR   SUPFAM; SSF47576; SSF47576; 1.
DR   SUPFAM; SSF51045; SSF51045; 1.
DR   PROSITE; PS00019; ACTININ_1; 1.
DR   PROSITE; PS00020; ACTININ_2; 1.
DR   PROSITE; PS50021; CH; 2.
DR   PROSITE; PS01159; WW_DOMAIN_1; 1.
DR   PROSITE; PS50020; WW_DOMAIN_2; 1.
DR   PROSITE; PS01357; ZF_ZZ_1; 1.
DR   PROSITE; PS50135; ZF_ZZ_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Actin-binding; Alternative promoter usage;
KW   Alternative splicing; Calcium; Cardiomyopathy; Cell junction;
KW   Cell membrane; Cytoplasm; Cytoskeleton; Disease mutation; Membrane;
KW   Metal-binding; Phosphoprotein; Polymorphism; Postsynaptic cell membrane;
KW   Reference proteome; Repeat; Synapse; Zinc; Zinc-finger.
FT   CHAIN           1..3685
FT                   /note="Dystrophin"
FT                   /id="PRO_0000076075"
FT   DOMAIN          15..119
FT                   /note="Calponin-homology (CH) 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00044"
FT   DOMAIN          134..240
FT                   /note="Calponin-homology (CH) 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00044"
FT   REPEAT          339..447
FT                   /note="Spectrin 1"
FT   REPEAT          448..556
FT                   /note="Spectrin 2"
FT   REPEAT          559..667
FT                   /note="Spectrin 3"
FT   REPEAT          719..828
FT                   /note="Spectrin 4"
FT   REPEAT          830..934
FT                   /note="Spectrin 5"
FT   REPEAT          943..1045
FT                   /note="Spectrin 6"
FT   REPEAT          1048..1154
FT                   /note="Spectrin 7"
FT   REPEAT          1157..1263
FT                   /note="Spectrin 8"
FT   REPEAT          1266..1367
FT                   /note="Spectrin 9"
FT   REPEAT          1368..1463
FT                   /note="Spectrin 10"
FT   REPEAT          1468..1568
FT                   /note="Spectrin 11"
FT   REPEAT          1571..1676
FT                   /note="Spectrin 12"
FT   REPEAT          1679..1778
FT                   /note="Spectrin 13"
FT   REPEAT          1779..1874
FT                   /note="Spectrin 14"
FT   REPEAT          1877..1979
FT                   /note="Spectrin 15"
FT   REPEAT          1992..2101
FT                   /note="Spectrin 16"
FT   REPEAT          2104..2208
FT                   /note="Spectrin 17"
FT   REPEAT          2211..2318
FT                   /note="Spectrin 18"
FT   REPEAT          2319..2423
FT                   /note="Spectrin 19"
FT   REPEAT          2475..2577
FT                   /note="Spectrin 20"
FT   REPEAT          2580..2686
FT                   /note="Spectrin 21"
FT   REPEAT          2689..2802
FT                   /note="Spectrin 22"
FT   REPEAT          2808..2930
FT                   /note="Spectrin 23"
FT   REPEAT          2935..3040
FT                   /note="Spectrin 24"
FT   DOMAIN          3055..3088
FT                   /note="WW"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00224"
FT   ZN_FING         3307..3354
FT                   /note="ZZ-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00228"
FT   REGION          1..240
FT                   /note="Actin-binding"
FT   REGION          63..72
FT                   /note="ANK2- and ANK-3 binding"
FT                   /evidence="ECO:0000250"
FT   REGION          1415..1913
FT                   /note="Interaction with SYNM"
FT                   /evidence="ECO:0000250"
FT   REGION          3058..3408
FT                   /note="Interaction with SYNM"
FT                   /evidence="ECO:0000250"
FT   REGION          3466..3518
FT                   /note="Binds to SNTB1"
FT   MOD_RES         3483
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         3490
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         3500
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         3612
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         3613
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:20068231"
FT   MOD_RES         3617
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         3623
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:23186163,
FT                   ECO:0000244|PubMed:24275569"
FT   MOD_RES         3624
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163,
FT                   ECO:0000244|PubMed:24275569"
FT   MOD_RES         3666
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:24275569"
FT   VAR_SEQ         1..3068
FT                   /note="Missing (in isoform 12, isoform 13, isoform 14,
FT                   isoform 15, isoform 16 and isoform 17)"
FT                   /evidence="ECO:0000303|PubMed:1319059,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8541829"
FT                   /id="VSP_017490"
FT   VAR_SEQ         1..2729
FT                   /note="Missing (in isoform 11)"
FT                   /id="VSP_060276"
FT   VAR_SEQ         1..2460
FT                   /note="Missing (in isoform 6, isoform 7, isoform 8, isoform
FT                   9 and isoform 10)"
FT                   /id="VSP_060275"
FT   VAR_SEQ         1..11
FT                   /note="MLWWEEVEDCY -> MED (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:2648158"
FT                   /id="VSP_006809"
FT   VAR_SEQ         1..11
FT                   /note="MLWWEEVEDCY -> MSEVSSD (in isoform 3)"
FT                   /id="VSP_060274"
FT   VAR_SEQ         1
FT                   /note="M -> MTEIILLIFFPAYFLN (in isoform 4)"
FT                   /id="VSP_006806"
FT   VAR_SEQ         1
FT                   /note="M -> MSARKLRNLSYKK (in isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_006808"
FT   VAR_SEQ         2..1357
FT                   /note="Missing (in isoform 4 and isoform 5)"
FT                   /id="VSP_006807"
FT   VAR_SEQ         2730..2739
FT                   /note="GVKELMKQWQ -> MLHRKTYHVK (in isoform 11)"
FT                   /id="VSP_060277"
FT   VAR_SEQ         3069..3075
FT                   /note="KVPYYIN -> MREQLKG (in isoform 12, isoform 13,
FT                   isoform 14, isoform 15, isoform 16 and isoform 17)"
FT                   /evidence="ECO:0000303|PubMed:1319059,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8541829"
FT                   /id="VSP_017491"
FT   VAR_SEQ         3409..3685
FT                   /note="Missing (in isoform 17)"
FT                   /id="VSP_060278"
FT   VAR_SEQ         3409..3518
FT                   /note="Missing (in isoform 7, isoform 10 and isoform 16)"
FT                   /id="VSP_046319"
FT   VAR_SEQ         3409..3421
FT                   /note="Missing (in isoform 9, isoform 13 and isoform 15)"
FT                   /evidence="ECO:0000303|PubMed:1319059,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8541829"
FT                   /id="VSP_017492"
FT   VAR_SEQ         3673..3685
FT                   /note="RNTPGKPMREDTM -> HNVGSLFHMADDLGRAMESLVSVMTDEEGAE (in
FT                   isoform 8, isoform 9, isoform 10, isoform 14, isoform 15
FT                   and isoform 16)"
FT                   /evidence="ECO:0000303|PubMed:1319059,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8541829"
FT                   /id="VSP_017493"
FT   VARIANT         18
FT                   /note="K -> N (in CMD3B; decreased thermodynamic stability;
FT                   accelerated unfolding, perturbed protein structure; no
FT                   effect on anchoring function)"
FT                   /evidence="ECO:0000269|PubMed:12359139,
FT                   ECO:0000269|PubMed:25340340"
FT                   /id="VAR_023537"
FT   VARIANT         32..62
FT                   /note="Missing (in BMD)"
FT                   /id="VAR_005146"
FT   VARIANT         54
FT                   /note="L -> R (in DMD)"
FT                   /evidence="ECO:0000269|PubMed:8401582"
FT                   /id="VAR_005147"
FT   VARIANT         118
FT                   /note="W -> R (in a patient with Becker muscular
FT                   dystrophy)"
FT                   /evidence="ECO:0000269|PubMed:21396098"
FT                   /id="VAR_065764"
FT   VARIANT         133
FT                   /note="Q -> P (in dbSNP:rs1800256)"
FT                   /evidence="ECO:0000269|PubMed:2668885"
FT                   /id="VAR_005148"
FT   VARIANT         165
FT                   /note="D -> V (in one patient with Becker muscular
FT                   dystrophy)"
FT                   /evidence="ECO:0000269|PubMed:12632325"
FT                   /id="VAR_023538"
FT   VARIANT         168
FT                   /note="A -> D (in BMD)"
FT                   /id="VAR_005149"
FT   VARIANT         171
FT                   /note="A -> P (in BMD)"
FT                   /evidence="ECO:0000269|PubMed:10573008"
FT                   /id="VAR_023539"
FT   VARIANT         231
FT                   /note="Y -> N (in BMD)"
FT                   /id="VAR_005150"
FT   VARIANT         279
FT                   /note="T -> A (in CMD3B)"
FT                   /evidence="ECO:0000269|PubMed:9170407"
FT                   /id="VAR_023540"
FT   VARIANT         334
FT                   /note="L -> F (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036353"
FT   VARIANT         365
FT                   /note="Q -> H (in dbSNP:rs1800266)"
FT                   /evidence="ECO:0000269|PubMed:7849724"
FT                   /id="VAR_005151"
FT   VARIANT         409
FT                   /note="T -> S (in dbSNP:rs34155804)"
FT                   /id="VAR_057642"
FT   VARIANT         495..534
FT                   /note="Missing (in BMD)"
FT                   /id="VAR_005152"
FT   VARIANT         573
FT                   /note="A -> V (in dbSNP:rs5972599)"
FT                   /id="VAR_057643"
FT   VARIANT         623
FT                   /note="L -> I (in dbSNP:rs1800259)"
FT                   /evidence="ECO:0000269|PubMed:2668885"
FT                   /id="VAR_005153"
FT   VARIANT         645
FT                   /note="D -> G (in DMD)"
FT                   /evidence="ECO:0000269|PubMed:7981690"
FT                   /id="VAR_023541"
FT   VARIANT         666
FT                   /note="S -> L (in dbSNP:rs34563188)"
FT                   /id="VAR_062110"
FT   VARIANT         715
FT                   /note="T -> S (in dbSNP:rs16998350)"
FT                   /id="VAR_057644"
FT   VARIANT         773
FT                   /note="K -> E (in DMD)"
FT                   /id="VAR_005154"
FT   VARIANT         784
FT                   /note="A -> G (in dbSNP:rs1800260)"
FT                   /evidence="ECO:0000269|PubMed:2668885"
FT                   /id="VAR_005155"
FT   VARIANT         882
FT                   /note="D -> G (in dbSNP:rs228406)"
FT                   /evidence="ECO:0000269|PubMed:2668885,
FT                   ECO:0000269|PubMed:3282674, ECO:0000269|PubMed:3428261"
FT                   /id="VAR_005156"
FT   VARIANT         1136
FT                   /note="T -> S (in dbSNP:rs3827462)"
FT                   /id="VAR_057645"
FT   VARIANT         1197
FT                   /note="V -> F (in dbSNP:rs1800262)"
FT                   /evidence="ECO:0000269|PubMed:2668885"
FT                   /id="VAR_005157"
FT   VARIANT         1219
FT                   /note="E -> Q (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036354"
FT   VARIANT         1245
FT                   /note="T -> I (in dbSNP:rs1800269)"
FT                   /id="VAR_005158"
FT   VARIANT         1278
FT                   /note="A -> P (in dbSNP:rs1800270)"
FT                   /id="VAR_005159"
FT   VARIANT         1377
FT                   /note="K -> N (in dbSNP:rs1800263)"
FT                   /evidence="ECO:0000269|PubMed:2668885"
FT                   /id="VAR_005160"
FT   VARIANT         1388
FT                   /note="F -> V (in dbSNP:rs28715870)"
FT                   /id="VAR_057646"
FT   VARIANT         1469
FT                   /note="Q -> L (in dbSNP:rs1057872)"
FT                   /evidence="ECO:0000269|PubMed:3282674"
FT                   /id="VAR_005161"
FT   VARIANT         1470
FT                   /note="R -> H (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036355"
FT   VARIANT         1672
FT                   /note="N -> K (in dbSNP:rs16990264)"
FT                   /evidence="ECO:0000269|PubMed:12354438"
FT                   /id="VAR_023542"
FT   VARIANT         1745
FT                   /note="R -> H (in dbSNP:rs1801187)"
FT                   /evidence="ECO:0000269|PubMed:2668885"
FT                   /id="VAR_005162"
FT   VARIANT         1844
FT                   /note="R -> S (in dbSNP:rs1801186)"
FT                   /evidence="ECO:0000269|PubMed:2668885"
FT                   /id="VAR_005163"
FT   VARIANT         2108
FT                   /note="R -> C (in dbSNP:rs16990169)"
FT                   /id="VAR_057647"
FT   VARIANT         2155
FT                   /note="R -> W (in dbSNP:rs1800273)"
FT                   /evidence="ECO:0000269|PubMed:12359139"
FT                   /id="VAR_005164"
FT   VARIANT         2164
FT                   /note="A -> V (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036356"
FT   VARIANT         2191
FT                   /note="R -> W"
FT                   /evidence="ECO:0000269|PubMed:7849724"
FT                   /id="VAR_005165"
FT   VARIANT         2299
FT                   /note="N -> T"
FT                   /evidence="ECO:0000269|PubMed:12359139"
FT                   /id="VAR_023543"
FT   VARIANT         2305..2366
FT                   /note="Missing (in DMD)"
FT                   /id="VAR_005166"
FT   VARIANT         2366
FT                   /note="K -> Q (in dbSNP:rs1800275)"
FT                   /evidence="ECO:0000269|PubMed:12359139,
FT                   ECO:0000269|PubMed:3282674"
FT                   /id="VAR_005167"
FT   VARIANT         2910
FT                   /note="E -> V (in dbSNP:rs41305353)"
FT                   /evidence="ECO:0000269|PubMed:12359139"
FT                   /id="VAR_005168"
FT   VARIANT         2912
FT                   /note="N -> D (in dbSNP:rs1800278)"
FT                   /evidence="ECO:0000269|PubMed:12359139"
FT                   /id="VAR_005169"
FT   VARIANT         2921
FT                   /note="H -> R (in BMD; dbSNP:rs1800279)"
FT                   /id="VAR_005170"
FT   VARIANT         2937
FT                   /note="Q -> R (in dbSNP:rs1800280)"
FT                   /evidence="ECO:0000269|PubMed:12359139,
FT                   ECO:0000269|PubMed:15772651, ECO:0000269|PubMed:7849724"
FT                   /id="VAR_005171"
FT   VARIANT         3228
FT                   /note="F -> L (in CMD3B)"
FT                   /evidence="ECO:0000269|PubMed:12359139"
FT                   /id="VAR_023544"
FT   VARIANT         3313
FT                   /note="C -> F (in DMD; results in highly reduced protein
FT                   levels and expression at the sarcolemma)"
FT                   /evidence="ECO:0000269|PubMed:12632325,
FT                   ECO:0000269|PubMed:24302611"
FT                   /id="VAR_023545"
FT   VARIANT         3335
FT                   /note="D -> H (in DMD; does not affect protein stability;
FT                   does not affect protein expression at the sarcolemma;
FT                   interaction with DAG1 is reduced)"
FT                   /evidence="ECO:0000269|PubMed:24302611,
FT                   ECO:0000269|PubMed:9851445"
FT                   /id="VAR_023546"
FT   VARIANT         3340
FT                   /note="C -> Y (in DMD; results in highly reduced protein
FT                   levels and expression at the sarcolemma)"
FT                   /evidence="ECO:0000269|PubMed:24302611,
FT                   ECO:0000269|PubMed:8817332"
FT                   /id="VAR_023547"
FT   VARIANT         3421
FT                   /note="A -> V (in BMD)"
FT                   /id="VAR_005172"
FT   CONFLICT        664
FT                   /note="Q -> QM (in Ref. 10; CAA29544)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2361
FT                   /note="G -> E (in Ref. 13; CAA38589)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3542
FT                   /note="P -> T (in Ref. 6; AAH70078)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3546
FT                   /note="M -> V (in Ref. 6; AAH70078)"
FT                   /evidence="ECO:0000305"
FT   HELIX           14..31
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   TURN            40..46
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   HELIX           48..58
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   HELIX           70..86
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   HELIX           96..100
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   HELIX           104..118
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   TURN            119..121
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   HELIX           122..131
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   HELIX           136..148
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   STRAND          158..160
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   HELIX           161..163
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   HELIX           167..176
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   HELIX           178..180
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   HELIX           183..187
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   HELIX           192..205
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   HELIX           215..218
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   STRAND          219..222
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   HELIX           225..236
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   STRAND          243..245
FT                   /evidence="ECO:0000244|PDB:1DXX"
FT   HELIX           339..365
FT                   /evidence="ECO:0000244|PDB:3UUN"
FT   HELIX           372..409
FT                   /evidence="ECO:0000244|PDB:3UUN"
FT   HELIX           414..452
FT                   /evidence="ECO:0000244|PDB:3UUN"
FT   HELIX           3050..3054
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   STRAND          3061..3065
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   STRAND          3071..3075
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   TURN            3076..3079
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   STRAND          3080..3084
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   HELIX           3086..3094
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   HELIX           3095..3098
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   HELIX           3104..3118
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   HELIX           3121..3123
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   HELIX           3126..3135
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   STRAND          3143..3146
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   HELIX           3147..3164
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   STRAND          3165..3168
FT                   /evidence="ECO:0000244|PDB:1EG4"
FT   HELIX           3171..3186
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   STRAND          3192..3195
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   HELIX           3196..3205
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   STRAND          3207..3209
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   HELIX           3211..3222
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   HELIX           3231..3247
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   HELIX           3251..3254
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   HELIX           3260..3269
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   TURN            3270..3272
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   HELIX           3278..3286
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   TURN            3290..3293
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   HELIX           3294..3304
FT                   /evidence="ECO:0000244|PDB:1EG3"
FT   MOD_RES         P11532-5:340
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         P11532-5:344
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         P11532-5:348
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         P11532-5:616
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         P11532-6:629
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         P11532-8:340
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         P11532-8:344
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         P11532-8:348
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         P11532-9:519
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
SQ   SEQUENCE   3685 AA;  426750 MW;  24FF7E83F1E6BF8D CRC64;
     MLWWEEVEDC YEREDVQKKT FTKWVNAQFS KFGKQHIENL FSDLQDGRRL LDLLEGLTGQ
     KLPKEKGSTR VHALNNVNKA LRVLQNNNVD LVNIGSTDIV DGNHKLTLGL IWNIILHWQV
     KNVMKNIMAG LQQTNSEKIL LSWVRQSTRN YPQVNVINFT TSWSDGLALN ALIHSHRPDL
     FDWNSVVCQQ SATQRLEHAF NIARYQLGIE KLLDPEDVDT TYPDKKSILM YITSLFQVLP
     QQVSIEAIQE VEMLPRPPKV TKEEHFQLHH QMHYSQQITV SLAQGYERTS SPKPRFKSYA
     YTQAAYVTTS DPTRSPFPSQ HLEAPEDKSF GSSLMESEVN LDRYQTALEE VLSWLLSAED
     TLQAQGEISN DVEVVKDQFH THEGYMMDLT AHQGRVGNIL QLGSKLIGTG KLSEDEETEV
     QEQMNLLNSR WECLRVASME KQSNLHRVLM DLQNQKLKEL NDWLTKTEER TRKMEEEPLG
     PDLEDLKRQV QQHKVLQEDL EQEQVRVNSL THMVVVVDES SGDHATAALE EQLKVLGDRW
     ANICRWTEDR WVLLQDILLK WQRLTEEQCL FSAWLSEKED AVNKIHTTGF KDQNEMLSSL
     QKLAVLKADL EKKKQSMGKL YSLKQDLLST LKNKSVTQKT EAWLDNFARC WDNLVQKLEK
     STAQISQAVT TTQPSLTQTT VMETVTTVTT REQILVKHAQ EELPPPPPQK KRQITVDSEI
     RKRLDVDITE LHSWITRSEA VLQSPEFAIF RKEGNFSDLK EKVNAIEREK AEKFRKLQDA
     SRSAQALVEQ MVNEGVNADS IKQASEQLNS RWIEFCQLLS ERLNWLEYQN NIIAFYNQLQ
     QLEQMTTTAE NWLKIQPTTP SEPTAIKSQL KICKDEVNRL SDLQPQIERL KIQSIALKEK
     GQGPMFLDAD FVAFTNHFKQ VFSDVQAREK ELQTIFDTLP PMRYQETMSA IRTWVQQSET
     KLSIPQLSVT DYEIMEQRLG ELQALQSSLQ EQQSGLYYLS TTVKEMSKKA PSEISRKYQS
     EFEEIEGRWK KLSSQLVEHC QKLEEQMNKL RKIQNHIQTL KKWMAEVDVF LKEEWPALGD
     SEILKKQLKQ CRLLVSDIQT IQPSLNSVNE GGQKIKNEAE PEFASRLETE LKELNTQWDH
     MCQQVYARKE ALKGGLEKTV SLQKDLSEMH EWMTQAEEEY LERDFEYKTP DELQKAVEEM
     KRAKEEAQQK EAKVKLLTES VNSVIAQAPP VAQEALKKEL ETLTTNYQWL CTRLNGKCKT
     LEEVWACWHE LLSYLEKANK WLNEVEFKLK TTENIPGGAE EISEVLDSLE NLMRHSEDNP
     NQIRILAQTL TDGGVMDELI NEELETFNSR WRELHEEAVR RQKLLEQSIQ SAQETEKSLH
     LIQESLTFID KQLAAYIADK VDAAQMPQEA QKIQSDLTSH EISLEEMKKH NQGKEAAQRV
     LSQIDVAQKK LQDVSMKFRL FQKPANFEQR LQESKMILDE VKMHLPALET KSVEQEVVQS
     QLNHCVNLYK SLSEVKSEVE MVIKTGRQIV QKKQTENPKE LDERVTALKL HYNELGAKVT
     ERKQQLEKCL KLSRKMRKEM NVLTEWLAAT DMELTKRSAV EGMPSNLDSE VAWGKATQKE
     IEKQKVHLKS ITEVGEALKT VLGKKETLVE DKLSLLNSNW IAVTSRAEEW LNLLLEYQKH
     METFDQNVDH ITKWIIQADT LLDESEKKKP QQKEDVLKRL KAELNDIRPK VDSTRDQAAN
     LMANRGDHCR KLVEPQISEL NHRFAAISHR IKTGKASIPL KELEQFNSDI QKLLEPLEAE
     IQQGVNLKEE DFNKDMNEDN EGTVKELLQR GDNLQQRITD ERKREEIKIK QQLLQTKHNA
     LKDLRSQRRK KALEISHQWY QYKRQADDLL KCLDDIEKKL ASLPEPRDER KIKEIDRELQ
     KKKEELNAVR RQAEGLSEDG AAMAVEPTQI QLSKRWREIE SKFAQFRRLN FAQIHTVREE
     TMMVMTEDMP LEISYVPSTY LTEITHVSQA LLEVEQLLNA PDLCAKDFED LFKQEESLKN
     IKDSLQQSSG RIDIIHSKKT AALQSATPVE RVKLQEALSQ LDFQWEKVNK MYKDRQGRFD
     RSVEKWRRFH YDIKIFNQWL TEAEQFLRKT QIPENWEHAK YKWYLKELQD GIGQRQTVVR
     TLNATGEEII QQSSKTDASI LQEKLGSLNL RWQEVCKQLS DRKKRLEEQK NILSEFQRDL
     NEFVLWLEEA DNIASIPLEP GKEQQLKEKL EQVKLLVEEL PLRQGILKQL NETGGPVLVS
     APISPEEQDK LENKLKQTNL QWIKVSRALP EKQGEIEAQI KDLGQLEKKL EDLEEQLNHL
     LLWLSPIRNQ LEIYNQPNQE GPFDVKETEI AVQAKQPDVE EILSKGQHLY KEKPATQPVK
     RKLEDLSSEW KAVNRLLQEL RAKQPDLAPG LTTIGASPTQ TVTLVTQPVV TKETAISKLE
     MPSSLMLEVP ALADFNRAWT ELTDWLSLLD QVIKSQRVMV GDLEDINEMI IKQKATMQDL
     EQRRPQLEEL ITAAQNLKNK TSNQEARTII TDRIERIQNQ WDEVQEHLQN RRQQLNEMLK
     DSTQWLEAKE EAEQVLGQAR AKLESWKEGP YTVDAIQKKI TETKQLAKDL RQWQTNVDVA
     NDLALKLLRD YSADDTRKVH MITENINASW RSIHKRVSER EAALEETHRL LQQFPLDLEK
     FLAWLTEAET TANVLQDATR KERLLEDSKG VKELMKQWQD LQGEIEAHTD VYHNLDENSQ
     KILRSLEGSD DAVLLQRRLD NMNFKWSELR KKSLNIRSHL EASSDQWKRL HLSLQELLVW
     LQLKDDELSR QAPIGGDFPA VQKQNDVHRA FKRELKTKEP VIMSTLETVR IFLTEQPLEG
     LEKLYQEPRE LPPEERAQNV TRLLRKQAEE VNTEWEKLNL HSADWQRKID ETLERLQELQ
     EATDELDLKL RQAEVIKGSW QPVGDLLIDS LQDHLEKVKA LRGEIAPLKE NVSHVNDLAR
     QLTTLGIQLS PYNLSTLEDL NTRWKLLQVA VEDRVRQLHE AHRDFGPASQ HFLSTSVQGP
     WERAISPNKV PYYINHETQT TCWDHPKMTE LYQSLADLNN VRFSAYRTAM KLRRLQKALC
     LDLLSLSAAC DALDQHNLKQ NDQPMDILQI INCLTTIYDR LEQEHNNLVN VPLCVDMCLN
     WLLNVYDTGR TGRIRVLSFK TGIISLCKAH LEDKYRYLFK QVASSTGFCD QRRLGLLLHD
     SIQIPRQLGE VASFGGSNIE PSVRSCFQFA NNKPEIEAAL FLDWMRLEPQ SMVWLPVLHR
     VAAAETAKHQ AKCNICKECP IIGFRYRSLK HFNYDICQSC FFSGRVAKGH KMHYPMVEYC
     TPTTSGEDVR DFAKVLKNKF RTKRYFAKHP RMGYLPVQTV LEGDNMETPV TLINFWPVDS
     APASSPQLSH DDTHSRIEHY ASRLAEMENS NGSYLNDSIS PNESIDDEHL LIQHYCQSLN
     QDSPLSQPRS PAQILISLES EERGELERIL ADLEEENRNL QAEYDRLKQQ HEHKGLSPLP
     SPPEMMPTSP QSPRDAELIA EAKLLRQHKG RLEARMQILE DHNKQLESQL HRLRQLLEQP
     QAEAKVNGTT VSSPSTSLQR SDSSQPMLLR VVGSQTSDSM GEEDLLSPPQ DTSTGLEEVM
     EQLNNSFPSS RGRNTPGKPM REDTM
//
